Global Calcium Channel Blocker Market - 2020-2027
|鈣離子通道拮抗劑的全球市場 (2020-2027年) Global Calcium Channel Blocker Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
心血管疾病的盛行率的上升及人們的生活方式的變化，預計推動鈣離子通道拮抗劑市場成長。高血壓，是心臟病相關的主要原因之一。根據世界衛生組織 (WHO) ，在全球約有11億3000萬人患高血壓病。再加上心血管疾病是主要的死因之一，2016年約有1,790萬人死亡。鈣拮抗劑，對該適應症有效。
The global calcium channel blocker market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Calcium channel blockers are medications which are used control high blood pressure, chest pain and arrhythmia. They are available through prescription and work by relaxing blood vessels and increase the blood and oxygen supply to the heart. This reduces the workload of the heart. It can be prescribed by itself or in combination with other medications to treat high blood pressure and angina. There are a few different types of calcium channel blockers and each works in a slightly different way. These are highly effective as compared to beta blockers in lowering the risk of cardiovascular mortality. They help to reduce the amount of calcium that goes into the cardiac muscle cells and cause them to relax. Changing lifestyle of people across all regions led to an increase in the number of stress related disease, which is a major factor, which in turn is anticipated to drive the calcium channel blocker market.
The global calcium channel blocker growth is driven by the emerging markets and huge investment in research and development are the factors responsible for the growth of this market. Moreover, the rising demand for improved healthcare infrastructure are expected to drive the market.
The increasing prevalence rate of cardiovascular diseases, is expected to drive the growth in the forecast period
The increasing prevalence rate of cardiovascular diseases and changing lifestyle of people is expected to boost the calcium channel blocker market growth. Hypertension often referred as the elevated blood pressure is one of the major causes associated with heart diseases. According to World Health Organization, approximately 1.13 billion of people globally have hypertension. Furthermore, cardiovascular diseases are one of the leading causes of the death and around 17.9 million people died in 2016 due to it. Calcium antagonist are known to be effective against this indication. Thus, the demand has been steadily growing for this market for better management of the cardiovascular diseases. These factors are driving the growth of the market in the forecast period.
Rising assistance to people with anxiety disorders or bipolar disorder expected to drive the market growth
A smaller population of people who do not have a heart condtiion could also benefit from calcium channel blockers. There is some indication they may work as mood stabilizers and be of assistance to people with anxiety disorders or bipolar disorder. The latter is particularly under investigation because some calcium channel blocker may be somewhat safer to administer to pregnant women than are most traditional mood stabilizers or antipsychotics. A few calcium channel blocker are useful in the treatment of migraine headaches, too. There are quite a few drugs that are considered calcium channel blockers and each may have its own profile of side effects, risks, and benefits. Some medications that make this list include verapamil, amlodipine and dilatiazem. Others are nifedipine, felodipine, and nicardipine. There are still more calcium channel blockers and others might arrive on the market if they are considered improvement on the present supply.
Major side effects of drugs is likely to hinder the market growth
On the contrary, side effects related to calcium channel blockers such as edema, headache, rapid heart rate, and constipation are likely to hamper the overall demand for calcium channel blocker market.
The Wall Street Journal (winter, l996) reported that patients who took calcium channel blockers had 60% more chance of dying of a heart attack. This is because calcium channel blocker drugs take a system that is functioning poorly and damage it even more. Many previous studies have associated calcium channel blockers with increased heart attacks, increased risk of breast cancer, increased suicide risk, and increased gastrointestinal bleeding. Short-acting versions of these drugs have been previously shown to be dangerous and now long-acting versions are being shown to be possibly dangerous as well. These factors restrict the market growth.
COVID-19 Impact Analysis
As the COVID-19 outbreak continues to endanger global health and hamper the world economy, there are concerns and reconsiderations for medication taken by patients with cardiometabolic disorders as they are more vulnerable to COVID-19. It has been widely observed that patients with existing cardiovascular diseases experience higher rates of complications due to COVID-19. Specifically, it has been found that patients with hypertension, diabetes, and other comorbidities are at higher risk of death from the virus. During the widespread COVID-19 pandemic, there have been worries about the potential of certain blood pressure medications such as calcium channel blocker. he Centers for Disease Control and Prevention (CDC) and the European Society of Cardiology (ESC) and its council on hypertension have released position statements saying "we should not be jumping to conclusions and should not be withholding life-saving therapies from patients." More importantly, two very recent studies attest that blood pressure drugs do not increase coronavirus risk. These factors are driving the market growth in the forecast period.
By drug class, the calcium channel blockeris market is classified into dihydropyridine (amlodipine (Norvasc), nifedipine (Procardia, Adalat), felodipine (Plendil)), nondihydropyridines (verapamil (Calan, Isoptin), diltiazem (Cardizem)), benzothizepine, phenylalkylamine and others.
Dihydropyridines segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Dihydropyridines target a specific type of calcium channel in the body. They cause the blood vessels to widen, lowering blood pressure. Dihydropyridine is known to exhibit more vasodilation and less negative ionotropic effect in sinoatrial and atrioventricular nodes. Amlodipine is the most common type of dihydropyridines.
Amlodipine is used with or without other medications to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Amlodipine belongs to a class of drugs known as calcium channel blockers. It works by relaxing blood vessels so blood can flow more easily.Amlodipine is also used to prevent certain types of chest pain (angina). It may help to increase your ability to exercise and decrease the frequency of angina a
Nifedipine is in a group of drugs called calcium channel blockers. It works by relaxing the muscles of your heart and blood vessels. Nifedipine is used to treat hypertension (high blood pressure) and angina (chest pain). Nifedipine may also be used for purposes not listed in this medication guide. However, Some tablet forms of nifedipine are made with a shell that is not absorbed or melted in the body. Part of the tablet shell may appear in your stool. This is a normal side effect of nifedipine and will not make the medication less effective.
Felodipine is a calcium channel blocker that is used to treat hypertension (high blood pressure) in adults. Lowering blood pressure can help lower your risk of a stroke or heart attack. Felodipine inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents.
On the basis of distribution channel, the calcium channel blockeris classified into hospital pharmacy, pharmacy stores, others.
The hospital pharmacy are expected to dominate the calcium channel blocker market during the forecast period
The hospital pharmacies held the largest share in the calcium channel blocker market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
North America region holds the largest market share global Calcium Channel Blocker
North America expected to hold a major market share in the global calcium Channel blocker market due to changing lifestyle among people and increasing prevalence rate of cardiovascular diseases. The adoption of sedentary lifestyle has serious implications on the health of people and are known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. According to the World Health Organization, around 60% - 85% of people, worldwide, have adopted a sedentary life. According to Centre for Disease Control and Prevention, around 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 US adults & 1 out 5 school student meets the guideline of physical activity. Heart disease is one of the leading causes of death in U.S., at least one person dies every 37 second due to cardiovascular disease, as reported by Centre for Disease Control and Prevention.
Asia Pacific is anticipated to expand at a significant growth rate during the forecast period. Change in lifestyle and the increase in obesity among the young population in Asia Pacific leads to hypertension and anxiety disorders. These are the major factors which are estimated to drive the demand for calcium channel blockers during the forecast period.
The calcium channel blocker market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include ClearSynth, GlaxoSmithKline Plc., Pfizer Inc., AbMole Bioscience, Lupin Pharmaceuticals, Inc., Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, and Arbor Pharmaceuticals LLC. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the calcium channel blocker globally.
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
The global calcium channel blocker report would provide an access to an approx. 63 market data table, 53 figures and 240 pages.
LIST NOT EXHAUSTIVE